Galectin Therapeutics | GALT - Aset Lancar

Keuangan

USD 3.32

USD 27.66M

USD 25.6M

USD 27.29M

Kewajiban Lancar

USD 14.62M

USD 71.74M

Dividen - Hasil

0

USD -9.17M

USD -7.43M

14

Eps Laba Per Saham

USD -0.2

Modal Dan Cadangan

USD -83.87M

Beban Bunga Utang

USD 1.27M

Pendapatan Bunga

USD -2.71M

USD 93.42M

Kapitalisasi Pasar

USD 208.6M

Batas Pemasukan

USD -12.37M

Biaya Operasional

USD 11.29M

Laba Operasional

USD -11.29M

Modal Saham Biasa

USD 61K

Laba Sebelum Pajak

USD -12.37M

Pendapatan Penjualan

4.02

Beban Penjualan Dan Administrasi

USD 1.48M

Kreditur Perdagangan

USD 3.7M

	Aset Lancar	Perubahan		Tanggal
AbbVie	USD 33.67B		140M	2026-06
Bristol-Myers Squibb	USD 29.77B		1.19B	2026-09
Galectin Therapeutics	USD 27.29M		1.83M	2024-06
Gilead Sciences	USD 16.55B		4.02B	2026-09
Immunic	USD 188.76M		165.89M	2026-03
Incyte	USD 5.52B		505.2M	2026-09
Merck	USD 36.68B		1.66B	2026-06